Semaglutide Dosage for Weight Loss: Your Complete Guide

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN • U.S. Navy veteran (13 years) • Author, The Book of Hormones • Founder, Gaya Wellness

Published May 29, 2025 • Updated May 3, 2026

If you are searching for semaglutide dosage for weight loss, let me be clear: the dose is not the treatment plan. The dose is one part of a titration and monitoring protocol. The mistake I see over and over is treating 2.4 mg like a finish line.

That is how women end up nauseated, constipated, under-eating protein, losing muscle, and blaming themselves when the plan falls apart. Wegovy can be a powerful medication. The STEP trials changed obesity medicine for a reason. But semaglutide is not supposed to be a race to maximum appetite suppression. It is supposed to be a carefully escalated medication layered onto nutrition, resistance training, sleep, labs, hormone context, and follow-up.

At Gaya Wellness, I want the medication to work without wrecking the rest of your physiology. That matters even more for women in perimenopause and menopause, because the metabolic target has moved. Your body changed – your approach needs to change with it.

The FDA-Labeled Wegovy Injection Schedule

For FDA-approved Wegovy injection, the labeled starting dose is 0.25 mg once weekly for 4 weeks. Then the dose typically increases to 0.5 mg weekly for weeks 5 through 8, 1 mg weekly for weeks 9 through 12, and 1.7 mg weekly for weeks 13 through 16. Maintenance begins at week 17 and onward. For weight reduction, the label lists 1.7 mg or 2.4 mg once weekly, with 2.4 mg as the usual recommended maintenance dose.

The important part is not just the numbers. The current 2026 prescribing information says to follow the escalation schedule to reduce gastrointestinal adverse reactions and to consider delaying escalation for 4 weeks if a patient does not tolerate a dose. It also says to consider treatment response and tolerability when selecting maintenance. You can read the current FDA Wegovy prescribing information here.

That means a clinician should not automatically push you upward because the calendar says it is time. Nausea, vomiting, constipation, reflux, dehydration, inability to eat, fatigue, and abdominal pain are not proof that the medication is “working hard.” They are signals that the plan needs adjustment.

Why 2.4 mg Is Not a Trophy

The highest Wegovy injection dose for weight reduction is 2.4 mg weekly, but the smartest dose is individualized. Some women need 2.4 mg to reach a meaningful metabolic response. Some do very well at 1.7 mg. Some need a slower escalation because their digestion, hydration, gallbladder risk, migraines, reflux, or work schedule cannot tolerate the standard pace.

This is what nobody tells you: more appetite suppression is not always better care. If you can barely eat, you are not building a sustainable metabolic system. If your protein intake collapses, your hair starts shedding, your workouts disappear, and your bowel movements stop, the dose may be winning the wrong game.

Inside Weight Loss Concierge, I treat semaglutide dosing as a protocol. We look at weight trend, waist, blood pressure, glucose and insulin markers when appropriate, side effects, menstrual or menopause symptoms, sleep, strength training, protein, constipation, and maintenance strategy. That is different from a refill mill that asks one question: “Want to go up?”

What the STEP Trials Actually Showed

The STEP trials are the reason semaglutide became central to modern medical weight loss. In STEP 1, published in the New England Journal of Medicine in 2021, Wilding and colleagues studied 1,961 adults with obesity or overweight without diabetes. Participants received once-weekly semaglutide 2.4 mg or placebo for 68 weeks, both with lifestyle intervention. Mean weight loss was 14.9% with semaglutide versus 2.4% with placebo. The PubMed record is available here.

That result was major. But read the design before copying the dose. Patients did not start at 2.4 mg. They titrated. They were monitored. They had lifestyle intervention. The trial result does not justify jumping ahead, stacking medications casually, or ignoring side effects because “the study dose was 2.4.”

STEP 5, published in Nature Medicine in 2022, extended the story to 104 weeks. Garvey and colleagues reported sustained weight reduction with semaglutide 2.4 mg plus behavioral intervention over 2 years. That matters because obesity is chronic. Stopping and starting, under-dosing, over-escalating, and treating the medication as a quick summer project usually backfires.

Side Effects Are Clinical Data

The common side effects are gastrointestinal: nausea, diarrhea, vomiting, constipation, abdominal pain, reflux, burping, bloating, headache, dizziness, and fatigue. Many are manageable. Some are not. The point is to respond early, not wait until you are afraid to eat dinner.

The Wegovy label also includes warnings for acute pancreatitis, gallbladder disease, hypoglycemia risk when combined with insulin or insulin secretagogues, kidney injury from dehydration, severe gastrointestinal adverse reactions, hypersensitivity reactions, diabetic retinopathy complications in patients with type 2 diabetes, heart rate increase, and pulmonary aspiration risk around anesthesia or deep sedation. It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.

That is why I do not like casual dose escalation. If you are vomiting, getting dizzy, having severe constipation, developing right upper abdominal pain, struggling to hydrate, or losing the ability to eat protein, the answer is not “push through.” The answer is to reassess the protocol.

Compounded Semaglutide Needs Extra Caution

Many women find Gaya after an unsafe or confusing compounded semaglutide experience. Some were given dosing in “units” without understanding milligrams. Some received multiple-dose vials with different concentrations. Some were told compounded versions were FDA-approved. They are not.

The FDA has repeatedly warned about unapproved GLP-1 drugs used for weight loss. Its current safety page says compounded drugs are not reviewed by FDA for safety, effectiveness, or quality before marketing, and it describes dosing errors with compounded injectable semaglutide products, including some adverse events requiring hospitalization. The FDA page is available here.

If you are using compounded medication, your clinician should be able to explain the concentration, dose in milligrams, injection volume, pharmacy source, storage, expiration, adverse-event plan, and why an FDA-approved product does or does not meet your medical need. If that conversation has never happened, that is not a patient education gap. That is a care gap. Our guide to affordable GLP-1 options explains why access matters, but access cannot come at the expense of basic medication safety.

The Menopause Muscle Problem

Here is where semaglutide dosing gets more nuanced for women over 40. Perimenopause and menopause are not just mood and hot flashes. They are body-composition events. Estrogen decline is associated with more visceral fat, changes in insulin sensitivity, sleep disruption, joint pain, and less forgiving recovery. A 2024 review in Menopause on obesity management in menopause describes how hormonal changes contribute to weight gain and fat redistribution, complicating treatment; the PubMed record is here.

Semaglutide can lower appetite so effectively that an under-muscled woman becomes more under-muscled unless the plan protects lean tissue. Every meaningful weight-loss intervention can include some fat-free mass loss. The clinical goal is to make fat loss dominant while protecting muscle with protein, progressive resistance training, creatine when appropriate, vitamin D and bone-risk review, and sleep.

This is why our midlife weight-loss care intersects with Hormonal Agency, Her Longevity, and education on HRT and weight loss. Semaglutide may quiet food noise. It does not rebuild muscle, fix hot flashes, correct sleep apnea, treat thyroid disease, or make your bones stronger by itself.

When I Hold the Dose

I am more likely to hold the dose when a patient is losing steadily, side effects are present but manageable, protein is barely adequate, constipation needs work, or the recent plateau is too short to mean anything. A two-week pause after a strong month is not failure. It is normal weight physiology.

I am also cautious when a woman is in a high-stress season, traveling, recovering from surgery, changing hormone therapy, increasing training, or dealing with poor sleep. Dose changes during chaos can make it hard to know what caused what. Sometimes the best clinical move is boring: hold, hydrate, fix bowel function, tighten protein, review labs, and reassess.

That is why articles like lose weight after 40, weight loss after menopause, and medical weight loss for women all come back to the same point. The medication helps. The architecture matters.

When I Consider Escalation

Escalation can be reasonable when the current dose is well tolerated, appetite and cravings have returned, nutrition is stable, constipation is controlled, hydration is good, the patient is strength training, and metabolic goals are not being met. I also want to know whether the issue is a true medication-response problem or a plan problem.

For example, a patient who is eating 60 grams of protein, lifting once a month, sleeping five hours, and drinking wine nightly does not need the same intervention as a patient eating 110 grams of protein, lifting three days weekly, sleeping seven hours, and stalled for 10 weeks. The first needs a protocol repair. The second may need a dose discussion.

Semaglutide is not punishment for having a body that resists weight loss. It is a medical tool. Used well, it can make the metabolic system more workable. Used poorly, it can become another version of diet culture with a prescription label.

FAQs

The Bottom Line

Semaglutide dosing for weight loss is a medical titration, not a race to 2.4 mg. The right protocol respects the Wegovy label, the STEP trial evidence, your side effects, your labs, your menopause stage, your muscle, and your life. If you are losing well on a lower dose, that is not “behind.” If you are sick every week on a higher dose, that is not success.

If you are reading this and recognizing your own story, the solution is not shame. It is better clinical supervision, better monitoring, and a plan built for the body you actually live in now.

Dr. Shweta Patel, MD, FACOG

Board-certified OB/GYN, U.S. Navy veteran, and founder of Gaya Wellness. Dr. Patel leads physician-managed programs in medical weight loss, hormone optimization, and longevity medicine for women in midlife and beyond.

You have not failed. Your plan did.